Aptevo Therapeutics Inc. APVO
1.15 USD -0.09 (-7.26%)
Nov 9, 2026, 1:47 PM EST
1.12 Day range 1.22
1.07 52-week range 28.08
- YTD
- -87.80%
- 1 year
- -95.65%
News
benzinga.com Aptevo Therapeutics Announces Substantial Reduction In Infusion-Related Reactions For Mipletamig Following Successive Refinements To Its Priming-Dose Regimen; Improvement Builds On Mipletamig's Already Favorable Safety And Tolerability Profile The improvement builds on mipletamig's already favorable safety and tolerability profile, including encouraging cytokine release syndrome (CRS) findings observed throughout its clinical development.…
benzinga.com Aptevo Reports 10 AML Patients Advanced To Stem Cell Transplant Following Treatment With Mipletamig In Combination With Venetoclax And Azacitidine Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing…
benzinga.com Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027 Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™
benzinga.com Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-market session. The company's market cap stands at $5.6 million. Nyxoah (NASDAQ:NYXH) shares increased by…
benzinga.com Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS". https://patentcenter.uspto.gov/applications/18255342/ifw/docs
benzinga.com Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of…- benzinga.com Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously
- benzinga.com Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals…
benzinga.com Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%, AIBZ +14.3%, BBIO +10%. Losers: AFJK -25.8%, VTAK -19%, APVO -18%, NQ -16.3%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…- benzinga.com Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)". https://patentcenter.uspto.gov/applications/17634631/ifw/docshttps://x.com/PatentGrants/status/2074946217625493850
benzinga.com Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)". https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/2059725536650547305- benzinga.com Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology Programs Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform
- benzinga.com Aptevo Therapeutic Announces 87% clinical benefit rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in…
benzinga.com Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Aptevo Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine In Newly Diagnosed AML Patients; Trials Deliver 86% Clinical Benefit Rate With Zero Patients Experiencing Common Symptom Of CRS Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo…
- benzinga.com 10 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies,…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session 
benzinga.com What's Going On With Aptevo Therapeutics Stock Today? Shares of Aptevo Therapeutics are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
benzinga.com US Stocks Mixed; Biohaven Shares Fall - benzinga.com Aptevo Therapeutics Presents Preliminary Results From Ongoing Phase 1b/2 RAINIER Study Evaluating Mipletamig In Combination With AZA/VEN For Newly Diagnosed AML Patients, At ASH Annual Meeting 100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability…
- benzinga.com Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of $(2.09) by 6.7 percent. This is a 99.38 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket 
benzinga.com Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket 
benzinga.com Crude Oil Moves Higher; US Weekly Jobless Claims Decline 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Dow Surges 150 Points; Korn Ferry Earnings Top Views - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session